KRAS and cancer: We then performed a deep targeted sequencing panel of 390 cancer‐related genes at an average depth of 678× (range: 370–821×), including 80 targeted treatment genes, 200 genes involved in druggable target‐related signaling pathways, 50 genes involved in DNA damage repair, 25 genes involved in epigenetics, 25 fusion genes, 10 other cancer‐related genes (e.g. EGFR, TP53, BRAF, PTEN, KRAS, and BRCA1).